Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
AbbVie
Institute of Hematology & Blood Diseases Hospital, China
University of Alabama at Birmingham
University of Utah
European Myeloma Network B.V.
University of Utah
UNC Lineberger Comprehensive Cancer Center
Thomas Jefferson University
University of Washington
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Tongji Hospital
Nanjing IASO Biotechnology Co., Ltd.
M.D. Anderson Cancer Center